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Abstract Aldosterone is thought to regulate cardiac work in-
dependently of sodium retention, though the mechanisms remain
to be known. In the present study, we have demonstrated that
aldosterone reinforces endothelin-mediated cardiac hypertrophy
with the increase in cell surface area and upregulation of the
transcripts characteristic of hypertrophy. We have also shown
that aldosterone augments c-Jun N-terminal kinase activation
induced by endothelin-1. Taken together, it is suggested that
aldosterone modulates cardiac hypertrophy, at least partially,
synergistically with extracellular signals that have been shown
to be involved in cardiac remodeling. " 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Cardiac hypertrophy is an adaptive response to pathologi-
cal conditions, including myocardial infarction, genetic muta-
tions of sarcomeric proteins, and hypertension. Various kinds
of hormones, growth factors and cytokines play critical roles
in cardiac hypertrophy, leading to cardiac remodeling charac-
terized by cardiac myocyte loss and interstitial ¢brosis.
As aldosterone (Aldo) receptor is highly expressed in the
heart [1,2], Aldo has been believed to function as a modulator
of cardiac work. A clinical study revealed that left ventricular
mass index is correlated with serum Aldo levels in patients
with hypertension [3], suggesting that Aldo transduces hyper-
trophic signals synergistically with other signals which are
involved in cardiac hypertrophy.
Accumulating evidence has revealed that endothelin-1, orig-
inally isolated as a vasoconstrictor [4], contributes to the de-
velopment of cardiac hypertrophy both in vitro and in vivo
[5]. In addition, endothelin-1 is known to be pathophysiolog-
ically involved in cardiovascular diseases such as failing heart,
considering that the inhibition of endothelin-1 prevents the
progression of heart failure [6^8]. Collectively, it could be
concluded that endothelin-1 functions as a modulator of car-
diac remodeling.
In the present study, we explored the crosstalk between
Aldo and endothelin-1 signals in cardiac hypertrophy by ana-
lyzing the morphological changes of cardiomyocytes and ex-
pression of skeletal actin [9] and brain natriuretic peptide
(BNP) [10], molecular markers of cardiac hypertrophy. And
we have demonstrated that Aldo augments endothelin-1-in-
duced JNK activation. These data suggest that Aldo directly
modulates cardiac remodeling, independently of sodium me-
tabolism.
2. Materials and methods
2.1. Cell culture
Primary cultures of neonatal cardiac myocytes were prepared as
described previously [11]. Brie£y, the ventricles of the hearts from
1-day-old Wistar rats were treated with trypsin and collagenase. Iso-
lated cells were collected and resuspended in M-199 containing 10%
calf serum (CS). Cultures were enriched with myocytes by preplating
for 60 min to deplete the non-myocyte population. Non-attached cells
were plated on 60-mm plastic culture dishes at a concentration of
1U106 cells/well and cultured in M-199 containing 10% CS for 24 h.
Immuno£uorescent analysis with anti-sarcomeric K-actinin revealed
that s 90% of cultured cells consist of cardiac myocytes (not shown).
After incubated in M-199 plus 10% CS for 24 h, cells were cultured in
CS-depleted M-199. All assays were performed in serum-depleted con-
dition.
Cells were pretreated with or without Aldo (Sigma) for 15 h, fol-
lowed by stimulation with endothelin-1 (Peptide Institute) for the
indicated time in the presence of the same concentration of Aldo.
To measure the cell surface areas, light photomicrographs of beat-
ing cells (250^300 cells from six visual ¢elds) were obtained by an
Olympus IMT-2 microscope and cell surfaces were traced by using
Macscope program.
2.2. Northern blot analysis
The probes for BNP, skeletal actin, and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were kindly gifted by Dr. K.R. Chien (Uni-
versity of California). Northern blot analyses were performed as de-
scribed previously [11]. Brie£y, 5 Wg of total RNA, prepared by the
acid guanidinium isothiocyanate^phenol^chloroform method [12], was
size-fractionated and blotted onto a nylon membrane (Hybond N+,
Amersham Pharmacia Biotech). After 3 h prehybridization, the mem-
branes were hybridized with the probes labeled with 32P. After mem-
branes were washed, autoradiography was performed at 380‡C. The
intensity of the bands for BNP and skeletal actin mRNA was mea-
sured and normalized by the intensity of the band for GAPDH
mRNA by using densitometry.
2.3. Western blot analysis
After pretreatment with Aldo followed by 15 min stimulation with
endothelin-1, cells were washed with ice cold phosphate-bu¡ered sa-
line and lysed with SDS^PAGE sample solution (200 Wl/60-mm dish).
Cell lysates were boiled for 5 min and proteins were separated on
SDS^PAGE and blotted onto a polyvinylidene di£uoride membrane.
After blocked in TBS-T containing 2% skim milk, membranes were
probed with antibodies speci¢c for phospho-extracellular signal-regu-
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lated kinase (ERK) (New England BioLabs), p38 mitogen-activated
protein kinases (MAPK) (New England BioLabs), or c-Jun NH2-ter-
minal kinase (JNK) (Promega). To show the e⁄cacy of the transfer,
the membranes were reprobed with anti-ERK, -p38 MAPK, or -JNK
antibody (Santa Cruz Biotechnology). The ECL system (Amersham)
was used for the detection.
2.4. Statistical analysis
Data are expressed as meanSS.E.M. Statistical analysis was per-
formed by t-test or ANOVA for multiple comparisons.
3. Results and discussion
3.1. Aldo augments endothelin-1-induced hypertrophy in
cultured cardiac myocytes
To analyze crosstalk between Aldo and endothelin-1 in car-
diac hypertrophy, we stimulated cultured cardiac myocytes
with endothelin-1 in the presence or absence of Aldo. Fig.
1A shows representative phase contrast micrographs of car-
diomyocytes. To quantify hypertrophic e¡ects, we measured
the cell surface area as described in Section 2. As shown in
Fig. 1B, endothelin-1 alone increased the cell surface area as
reported previously [9]. Though Aldo alone did not show any
e¡ects, cells costimulated with Aldo and endothelin-1 showed
a more marked increase in surface area, compared with those
treated with endothelin-1 alone. Furthermore, pretreatment
with various concentration of Aldo revealed the dose depen-
dence of the increase in surface area as shown in Fig. 1C.
Surface area was signi¢cantly increased when pretreated
with 100 nM Aldo. These data suggest that Aldo modulates
cardiac hypertrophy, synergistically with endothelin-1.
In order to clarify the positive e¡ects of Aldo on hyper-
trophic phenotype, we examined the expression of transcripts
characteristic of cardiac hypertrophy. Cells were stimulated
with or without endothelin-1 in the presence or absence of
Aldo. Total RNA was Northern-blotted for BNP and skeletal
actin mRNA as hypertrophic markers. As shown in Fig. 2A,
Aldo augmented the upregulation of BNP and skeletal actin
mRNA by endothelin-1. The expression of GAPDH mRNA
was not a¡ected by Aldo. To con¢rm this e¡ect, we quanti¢ed
the band intensity of BNP and skeletal actin mRNA normal-
ized by that of GAPDH. As shown in Fig. 2B, the endothelin-
1-induced increase in BNP and skeletal actin mRNA was sig-
ni¢cantly enhanced by Aldo. Next we examined the dose-de-
pendent e¡ect of Aldo on cardiac hypertrophy in the presence
of endothelin-1. Quanti¢cation of the bands for BNP and
skeletal actin mRNA intensities were shown in Fig. 2C.
Aldo enhanced endothelin-1-induced hypertrophy in a dose-
dependent manner. Of note, Aldo has a synergistic e¡ect with
endothelin-1 on cardiac hypertrophy under its physiological
conditions.
3.2. Treatment with aldosterone reinforced phosphorylation of
JNK
In cardiac myocytes, previous studies have reported that
endothelin-1 transduces hypertrophic signals through ERK,
p38 MAPK, and JNK [13,14]. To explore the molecular
mechanisms of positive e¡ects of Aldo on endothelin-1-medi-
ated cardiac hypertrophy, we analyzed the signaling pathway
activated by endothelin-1. After stimulation with endothelin-1
with or without pretreatment of Aldo, activation of MAPKs
was analyzed. As shown in Fig. 3A, endothelin-1 alone acti-
vated ERK and JNK while p38 MAPK was activated to a
lesser extent. Aldo augmented JNK activation by endothelin-
1, but not ERK or p38 MAPK. We quanti¢ed the band in-
tensity of phosphorylated JNK normalized by that of total
JNK. As shown in Fig. 3B, endothelin-1 alone signi¢cantly
activated JNK as reported previously [13], interestingly, endo-
thelin-1-mediated JNK activation was signi¢cantly enhanced
by Aldo.
Though Aldo binds to glucocorticoid receptor (GR) as well
as mineralocorticoid receptor, it is unlikely that Aldo aug-
mented endothelin-1-mediated hypertrophy through GR, be-
cause of the low a⁄nity of Aldo to GR. The Kd value of Aldo
Fig. 1. Pretreatment of Aldo increases cell surface area in endothe-
lin-1 (ET-1)-induced cardiac myocyte hypertrophy. A: Cardiomyo-
cytes were stimulated with (+) or without (3) 10 nM ET-1 in the
presence (+) or absence (3) of 1 WM Aldo for 24 h. Beating cells
were identi¢ed as cardiomyocytes and examined with an Olympus
IMT-2 microscope. Representative light photomicrographs of car-
diac myocytes are shown. B: Cells were cultured under the condi-
tions as described in A. Cardiomyocytes (250^300 cells for each
condition) were traced and cell surface areas were measured using
the Macscope program. *P6 0.05 versus endothelin-1 alone. C:
Cells were cultured at indicated concentrations of Aldo in the pres-
ence of 10 nM ET-1. Cell surface areas were measured as described
in B. *P6 0.05 versus endothelin-1 alone.
FEBS 26307 17-7-02
Y. Oshima et al./FEBS Letters 524 (2002) 123^126124
to GR is more than 300 nM in vitro [15]. However, Aldo-
induced cardiomyocyte hypertrophy is realized at 10^100 nM
of Aldo (Figs. 1C and 2C). Interestingly, in the heart, the
Aldo concentration is reported to be about 16 nM [16], 17-
fold higher than the mean plasma level, possibly because of
the slower degradation in the heart. Taking account of its
paracrine e¡ect, the data shown in this study could be phys-
iologically suggestive.
Previously it was revealed that Aldo induces cardiac hyper-
trophy under high glucose culture [17]. Interestingly, high
glucose culture also enhances JNK activity [18], similar to
endothelin-1 stimulation, proposing the hypothesis that JNK
plays an important role in Aldo-mediated cardiac hypertro-
phy. The causality has not been substantially documented
because a JNK-speci¢c inhibitor is not available. However,
this hypothesis was supported by the experiment with BAP-
TA-AM. Interestingly, it is revealed, using BAPTA-AM, that
angiotensin II, an agonist of the seven-transmembrane recep-
tor similar to endothelin-1, stimulates calcium-dependent ac-
tivation of JNK [19]. It is also reported that intracellular in-
crease of calcium ion is required for JNK-mediated cardiac
hypertrophy by angiotensin II [20]. Importantly, BAPTA-AM
inhibited hypertrophic phenotype modulation induced by co-
stimulation with endothelin-1 and Aldo, associated with the
inhibition of JNK activity (not shown). Taken together with
the previous report that JNK is a critical regulator of endo-
thelin-1-induced cardiac hypertrophy [13], it could be sup-
posed that Aldo augments endothelin-1-mediated cardiac hy-
pertrophy, at least partially, by reinforcing JNK activation.
Pathophysiologically, left ventricular mass index is corre-
lated with serum Aldo levels in patients with hypertension
[3]. Moreover, Aldo antagonists are reported to decrease left
ventricular mass index [21,22]. These studies suggest that Aldo
contributes to pathological hypertrophy in vivo, though fur-
ther studies are required to reveal the molecular mechanism.
Interestingly, subcutaneous administration of Aldo upregu-
lates endothelin-1, leading to cardiac remodeling [23,24].
Combined with the present study, it is possible that Aldo
Fig. 2. Aldo enhances BNP and skeletal actin mRNA induction by
endothelin-1 (ET-1): A. Cardiomyocytes were stimulated with (+)
or without (3) 10 nM ET-1 in the presence (+) or absence (3) of
1 WM Aldo for 24 h. The expression of BNP, skeletal actin (sk-ac-
tin), and GAPDH mRNA was examined by Northern blot analyses.
B: Relative intensity of the bands for BNP and skeletal actin
mRNA were assessed as the ratio to the intensity for GAPDH. The
results were expressed as relative intensity over ET-1 alone.
*P6 0.05 versus ET-1 alone. C: Cells were pretreated with 0, 10,
102, or 103 nM Aldo, followed by stimulation with 10 nM ET-1.
The expression of BNP, sk-actin, and GAPDH mRNA was exam-
ined by Northern blot analyses. Relative intensity of the bands for
BNP and skeletal actin mRNA was assessed as the ratio to the in-
tensity for GAPDH. The results are expressed as relative intensity
over 0 nM Aldo. *P6 0.05 versus 0 nM Aldo.
Fig. 3. Treatment with Aldo reinforces phosphorylation of JNK. A:
After pretreatment with (+) or without (3) Aldo (1 WM) for 15 h,
cells were stimulated with endothelin-1 (ET-1) for 15 min. Cell ly-
sates were immunoblotted, as described in Section 2, using antibody
against phospho-speci¢c ERK1/2 (P-ERK), p38 MAPK (P-p38), or
JNK (P-JNK). Membranes were reprobed with anti-ERK1/2
(ERK), -p38 (p38), or -JNK (JNK) antibody to show the e⁄cacy of
blotting. Representative data are shown. B: Relative intensity of the
bands for phosphorylated JNK was assessed as the ratio to the in-
tensity for bands for total JNK. The results are expressed as relative
intensity over ET-1 alone. *P6 0.05 versus ET-1 alone.
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may not only augment the e¡ect of endothelin-1 but increase
endothelin-1 concentration, suggesting that Aldo may pro-
mote cardiac hypertrophy in vivo both by upregulating endo-
thelin-1 and by reinforcing the hypertrophic e¡ects of endo-
thelin-1.
In summary, we showed that activation of the Aldo system
leads to the augmentation of endothelin-1-mediated cardiac
hypertrophy with the reinforcement of JNK activation. This
is the ¢rst demonstration of crosstalk between the Aldo sys-
tem and endothelin-1 signals in cardiac hypertrophy.
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